Compare Boston Scientific Corporation (BSX) vs Caesars Entertainment Inc (CZR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs Caesars Entertainment Inc — how do they compare? Boston Scientific Corporation trades at $42.81 (market cap $66.37B), while Caesars Entertainment Inc trades at $30 (market cap $6.08B). The key difference: Boston Scientific Corporation is far larger — about 10.9× Caesars Entertainment Inc's market cap, and Caesars Entertainment Inc is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.
| BSX | CZR | |
|---|---|---|
Market Cap | $66.37B | $6.08B |
Sector | Health | Consumer Cyclical |
52-Week High | $108.14 | $30.41 |
52-Week Low | $42.63 | $18.14 |
Enterprise Value | $75.94B | $30.14B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
Caesars Entertainment (CZR) trades at $29.66, down 0.6% on the day, with a mixed technical picture showing bullish moving averages but neutral oscillators. The company faces fundamental challenges with three consecutive quarterly earnings misses and negative net income margins, though valuation ratios appear attractive with P/E of 10.42 and P/S of 0.53. Recent developments include the opening of Caesars Republic Lake Tahoe and a pending $17.6 billion acquisition by Fertitta Entertainment.
CZR presents a complex investment case with analyst consensus leaning cautious (33% buy, 67% hold) despite a $31.27 price target suggesting modest upside. The pending acquisition provides a potential floor, but ongoing profitability challenges and competitive pressures in the gaming sector warrant careful monitoring of Q2 2026 earnings due July 28, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About Caesars Entertainment Inc
Caesars Entertainment includes around 50 domestic gaming properties across Las Vegas (50% of 2021 EBITDAR before corporate and digital expenses) and regional (63%) markets. Additionally, the company hosts managed properties and digital assets, the later of which produced material EBITDA losses in 2021. Caesars' U.S. presence roughly doubled with the 2020 acquisition by Eldorado, which built its first casino in Reno, Nevada, in 1973 and expanded its presence through prior acquisitions to over 20 properties before merging with legacy Caesars. Caesars' brands include Caesars, Harrah's, Tropicana, Bally's, Isle, and Flamingo. Also, the company owns the U.S. portion of William Hill (it plans to sell the international operation in 2022), a digital sports betting platform.
Read more on CZR →
